DK1592441T3 - Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf - Google Patents

Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf

Info

Publication number
DK1592441T3
DK1592441T3 DK04749316.8T DK04749316T DK1592441T3 DK 1592441 T3 DK1592441 T3 DK 1592441T3 DK 04749316 T DK04749316 T DK 04749316T DK 1592441 T3 DK1592441 T3 DK 1592441T3
Authority
DK
Denmark
Prior art keywords
listeria
attenuated
vaccines
entry
phagocytic cells
Prior art date
Application number
DK04749316.8T
Other languages
English (en)
Inventor
Thomas W Dubensky Jr
Dirk G Brockstedt
David Cook
Original Assignee
Aduro Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech filed Critical Aduro Biotech
Application granted granted Critical
Publication of DK1592441T3 publication Critical patent/DK1592441T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
DK04749316.8T 2003-02-06 2004-02-06 Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf DK1592441T3 (da)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US44605103P 2003-02-06 2003-02-06
US44915303P 2003-02-21 2003-02-21
US49008903P 2003-07-24 2003-07-24
US51186903P 2003-10-15 2003-10-15
US51171903P 2003-10-15 2003-10-15
US51191903P 2003-10-15 2003-10-15
US54151504P 2004-02-02 2004-02-02
PCT/US2004/003429 WO2004110481A2 (en) 2003-02-06 2004-02-06 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof

Publications (1)

Publication Number Publication Date
DK1592441T3 true DK1592441T3 (da) 2012-05-14

Family

ID=33556840

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04749316.8T DK1592441T3 (da) 2003-02-06 2004-02-06 Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf

Country Status (13)

Country Link
US (2) US7691393B2 (da)
EP (1) EP1592441B1 (da)
JP (2) JP4545151B2 (da)
KR (1) KR101192652B1 (da)
AT (1) ATE552843T1 (da)
AU (1) AU2004246999B2 (da)
CA (1) CA2515369C (da)
DK (1) DK1592441T3 (da)
ES (1) ES2382332T3 (da)
HK (1) HK1082187A1 (da)
MX (1) MXPA05008342A (da)
PT (1) PT1592441E (da)
WO (1) WO2004110481A2 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
JP2004500405A (ja) * 2000-03-29 2004-01-08 ザ　トラスティーズ　オブ　ザ　ユニバーシティー　オブ　ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
AU2003240971A1 (en) * 2002-05-29 2003-12-19 Univ California Attenuated listeria spp. and methods for using the same
EP1592441B1 (en) * 2003-02-06 2012-04-11 Aduro Biotech Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4839209B2 (ja) * 2003-02-06 2011-12-21 アンザ セラピューティクス，インコーポレイテッド 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
JP2008516614A (ja) * 2004-10-18 2008-05-22 メディミューン，インコーポレーテッド リステリア増殖のための高細胞密度法
US20060270040A1 (en) * 2005-05-26 2006-11-30 Conjugon, Inc. Compositions and methods for treating tissue
GB2451014B (en) * 2006-03-01 2010-12-29 Anza Therapeutics Inc Engineered Listeria comprising a modified ActA-antigen fusion protein and its use as a vaccine
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
WO2008094188A2 (en) 2006-07-17 2008-08-07 Anza Therapeutics, Inc. Methods and compositions using listeria for enhancing immunogenicity by prime boost
WO2008019131A2 (en) * 2006-08-04 2008-02-14 The Trustees Of The University Of Pennsylvania Methods and compositions for treating ige-mediated diseases
EP2977456B1 (en) * 2006-08-15 2017-10-25 The Trustees Of The University Of Pennsylvania Compositions comprising hmw-maa and fragments thereof for treating cancer
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
WO2008066774A2 (en) * 2006-11-22 2008-06-05 The Regents Of The University Of California INTERFERON-β PRODUCTION MODULATING LISTERIA STRAINS AND METHODS FOR USING SAME
US20110182847A1 (en) * 2007-06-15 2011-07-28 Randolph Noelle Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens
WO2009018465A1 (en) * 2007-07-31 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Vaccination with killed but metabolically active (kbma) protozoans with toll-like receptor agonists
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2283112B1 (en) 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
EP2853269B1 (en) 2008-05-19 2019-05-01 Advaxis, Inc. Dual delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by mutation of dal/dat and deletion of ActA comprising a nucleic acid molecule encoding an listeriolysin O - prostate specific anigen fusion protein
JP5539411B2 (ja) 2009-03-04 2014-07-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 血管新生因子を含む組成物およびその使用方法
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
JP5977737B2 (ja) 2010-05-23 2016-08-24 アデュロ バイオテック 癌の補助薬物療法でリステリアを使用する方法および組成物
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
WO2012068360A1 (en) 2010-11-17 2012-05-24 Aduro Biotech Methods and compositions for inducing an immune response to egfrviii
EP2683400A4 (en) 2011-03-11 2014-09-17 Advaxis ADJUVANZIA ON LISTERIA BASE
KR101898754B1 (ko) 2011-05-23 2018-09-13 레고 에이/에스 증강 현실을 위한 완구 구축 시스템
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
CN107250366A (zh) 2014-10-14 2017-10-13 宾夕法尼亚大学理事会 重组李斯特菌疫苗菌株及其用于癌症免疫疗法的方法
EP3215139B1 (en) 2014-11-03 2020-08-19 Cerus Corporation Compositions and methods for improved car-t cell therapies
JP2018512165A (ja) 2015-04-13 2018-05-17 アデュロ バイオテック，インコーポレイテッド 癌の治療のための免疫原性融合タンパク質
US10105427B2 (en) 2015-04-13 2018-10-23 Aduro Biotech, Inc. Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same
AU2016283389B2 (en) 2015-06-26 2022-09-15 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
KR20180107102A (ko) 2015-12-16 2018-10-01 그릿스톤 온콜로지, 인코포레이티드 신생항원 동정, 제조, 및 용도
EP3589297A1 (en) 2017-03-03 2020-01-08 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
MX2020003100A (es) 2017-09-19 2020-08-20 Advaxis Inc Composiciones y metodos para la liofilizacion de bacterias o cepas de listeria.
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
CN116571191A (zh) 2017-12-29 2023-08-11 塞鲁斯公司 用于处理生物流体的***和方法
CN112074737A (zh) 2018-03-09 2020-12-11 阿德瓦希斯公司 用于评估李斯特菌菌株的减毒和感染性的组合物和方法
US20210239681A1 (en) 2018-04-27 2021-08-05 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
CN112533939B (zh) * 2018-08-02 2024-03-19 苏州若泰医药科技有限公司 一种基于减毒李斯特菌激活的抗原提呈细胞的肿瘤免疫治疗组合物、制备方法和应用
CN114269394A (zh) 2019-06-28 2022-04-01 塞鲁斯公司 用于实现生物流体处理装置的***和方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN113845589B (zh) * 2021-08-20 2023-04-07 扬州大学 SmcL单克隆抗体、分泌该抗体的杂交瘤细胞株及其应用和竞争ELISA检测方法
CN114250244A (zh) * 2021-12-14 2022-03-29 浙江农林大学 以重组减毒单増李斯特菌为载体的结肠癌疫苗及制备方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545987A (en) * 1983-12-20 1985-10-08 Advanced Genetics Research Institute Psoralen inactivated double-stranded RNA viral vaccines
US4556556A (en) * 1984-03-23 1985-12-03 Advanced Genetics Research Institute Vaccine for the prevention of vesicular stomatitis virus infection
US5106619A (en) * 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4791062A (en) * 1985-02-28 1988-12-13 Diamond Scientific Co. FVR vaccine
DE3886363T3 (de) 1987-11-18 2004-09-09 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville NANBV-Diagnostika
DK189788D0 (da) 1988-04-07 1988-04-07 Wolf Watz Hans Vaccine
KR0185373B1 (ko) 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
CA2017157C (en) 1989-05-18 2003-07-29 Michael Houghton Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
US5180819A (en) * 1989-12-22 1993-01-19 The Trustees Of Columbia University In The City Of New York Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
US5830702A (en) * 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
FR2686896B1 (fr) 1992-01-31 1995-01-06 Pasteur Institut Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
US5399719A (en) * 1993-06-28 1995-03-21 Steritech, Inc. Compounds for the photodecontamination of pathogens in blood
US5593823A (en) * 1993-06-28 1997-01-14 Cerus Corporation Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US6150170A (en) * 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US5877159A (en) * 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US6177441B1 (en) * 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
EP0773716A4 (en) 1995-06-07 1999-08-04 Cerus Corp TREATMENT OF RED BLOOD CELL SOLUTIONS WITH ANTIVRAL ACTIVE SUBSTANCES
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
AU1152397A (en) 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
AU703769B2 (en) * 1996-01-05 1999-04-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mesothelium antigen and methods and kits for targeting it
US5843459A (en) * 1996-01-19 1998-12-01 Human Gene Therapy Research Institute Differential inactivation of nucleic acids by chemical modification
CA2249412A1 (en) * 1996-03-22 1997-09-25 Yale University Methods for inducing immune responsiveness in a subject
WO1997035619A1 (en) * 1996-03-28 1997-10-02 Genitrix, L.L.C. Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
EP0808897A1 (en) * 1996-05-21 1997-11-26 I.D.M. Immuno-Designed Molecules New antigen presenting cells, a process for preparing the same and their use as cellular vaccines
KR20000022445A (ko) * 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
GB9615022D0 (en) 1996-07-17 1996-09-04 Mini Agriculture & Fisheries Vaccine preparations
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
WO1998005795A1 (en) * 1996-08-02 1998-02-12 The Center For Blood Research, Inc. Enrichment of dendritic cells from blood
DE19635676A1 (de) * 1996-09-03 1998-03-05 Basf Ag Feste geschäumte Wirkstoffzubereitungen
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US6514987B1 (en) * 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
ES2196530T3 (es) 1997-01-06 2003-12-16 Cerus Corp Compuestos de ruptura para inactivar patogenos.
GB9700939D0 (en) 1997-01-17 1997-03-05 Microbial Technics Limited Therapy
AU6050398A (en) 1997-01-31 1998-08-25 Vanderbilt University Method of delivering antigens for vaccination with a live vector
CN1270630A (zh) 1997-07-21 2000-10-18 塞鲁斯公司 处理白细胞的方法、白细胞组合物及其应用方法
EP0902086A1 (en) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
DE69819360T2 (de) * 1997-11-20 2004-08-19 Cerus Corp., Concord Neue psoralene zur inaktivierung von pathogenen
DE19754938B4 (de) 1997-12-11 2006-04-20 Christoph von Dr. Eichel-Streiber TGC-Verfahren zur Induktion einer zielgerichteten, somatischen Transgenität
US6143551A (en) * 1997-12-29 2000-11-07 Schering Aktiengesellschaft Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria
AU745209B2 (en) 1998-01-06 2002-03-14 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
WO1999047646A1 (en) 1998-03-20 1999-09-23 Ludwig Institute For Cancer Research Processes for improved presentation of antigens by dendritic cells
WO1999050392A1 (en) * 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US20020155108A1 (en) * 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
US6254863B1 (en) 1998-08-12 2001-07-03 Loma Linda University Non-virulent Porphyromonas gingivalis mutant
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
GB9918283D0 (en) 1999-08-03 1999-10-06 Int Centre Genetic Eng & Bio Hsv vaccines
AU7856100A (en) 1999-10-04 2001-05-10 Vion Pharmaceuticals, Inc. Methods for treating solid tumors with irradiation and bacteria
DE19949594A1 (de) 1999-10-14 2001-04-26 Deutsches Krebsforsch Rekombinante attenuierte Listerien zur Immuntherapie
US20030077263A1 (en) * 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2004500405A (ja) 2000-03-29 2004-01-08 ザ　トラスティーズ　オブ　ザ　ユニバーシティー　オブ　ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
CN1440419A (zh) * 2000-05-04 2003-09-03 哈佛大学校长及研究员协会 治疗和预防细菌感染的化合物和方法
EP1320602A2 (en) * 2000-09-21 2003-06-25 The Regents Of The University Of California Spas-1 cancer antigen
AU2002224851A1 (en) * 2000-11-14 2002-05-27 Universite Libre De Bruxelles Generation and use of dendritic cells
CA2434256A1 (en) * 2000-12-21 2003-07-31 David Cook Methods for inactivation of pathogens in biological materials
US6783765B2 (en) * 2001-03-23 2004-08-31 Council Of Scientific And Industrial Research Process for the preparation of a vaccine for the treatment of tuberculosis and other intracellular infections diseases and the vaccine produced by the process
AU2002249531A1 (en) * 2001-04-02 2002-10-28 Alimentary Health Limited Immunotherapy based on dendritic cells
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
US20040022761A1 (en) * 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US7413869B2 (en) * 2002-04-05 2008-08-19 Dendreon Corporation Method for determining potency of antigenic presenting cell based vaccines
US7425449B2 (en) * 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
AU2003240971A1 (en) * 2002-05-29 2003-12-19 Univ California Attenuated listeria spp. and methods for using the same
US20040009194A1 (en) * 2002-06-21 2004-01-15 Jean-Marie Andrieu Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus
AU2002950473A0 (en) 2002-07-26 2002-09-12 Commonwealth Scientific And Industrial Research Organisation Expression system
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4839209B2 (ja) * 2003-02-06 2011-12-21 アンザ セラピューティクス，インコーポレイテッド 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
EP1592441B1 (en) * 2003-02-06 2012-04-11 Aduro Biotech Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
JP2007509067A (ja) 2003-10-15 2007-04-12 メディミューン，インコーポレーテッド リステリアに基づくＥｐｈＡ２ワクチン
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
AU2004314347B2 (en) 2003-12-24 2011-05-19 Aduro Biotech, Inc. Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
EP1732580A4 (en) 2003-12-24 2008-01-23 Medimmune Inc EPHA2 VACCINES
WO2005092372A2 (en) 2004-02-06 2005-10-06 Cerus Corporation Modified bacillus anthracis vaccine compositions and methods of use thereof
US20070031457A1 (en) * 2004-02-06 2007-02-08 Dubensky Thomas W Jr Modified Bacillus anthracis, vaccine compositions and methods of use thereof

Also Published As

Publication number Publication date
CA2515369A1 (en) 2004-12-23
MXPA05008342A (es) 2006-02-28
ES2382332T3 (es) 2012-06-07
ATE552843T1 (de) 2012-04-15
EP1592441A2 (en) 2005-11-09
EP1592441B1 (en) 2012-04-11
KR20050105460A (ko) 2005-11-04
KR101192652B1 (ko) 2012-10-19
US20110201092A1 (en) 2011-08-18
JP2007503846A (ja) 2007-03-01
JP2007125040A (ja) 2007-05-24
JP4545151B2 (ja) 2010-09-15
WO2004110481A2 (en) 2004-12-23
CA2515369C (en) 2015-03-31
US20040228877A1 (en) 2004-11-18
WO2004110481A3 (en) 2005-03-03
PT1592441E (pt) 2012-05-21
AU2004246999A1 (en) 2004-12-23
US7691393B2 (en) 2010-04-06
HK1082187A1 (en) 2006-06-02
AU2004246999B2 (en) 2010-06-10
US8287883B2 (en) 2012-10-16

Similar Documents

Publication Publication Date Title
DK1592441T3 (da) Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf
Brockstedt et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity
NO20031646L (no) Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol
IN2014DN08830A (da)
RU2009138327A (ru) Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака
Bonaldo et al. The yellow fever 17D virus as a platform for new live attenuated vaccines
IL202978A0 (en) West nile virus vaccine
HUP0101619A2 (hu) Adjuvánskészítmények
Guy et al. Dengue vaccine prospects: a step forward
EE05633B1 (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
CY1110995T1 (el) Ασφαλη μεταλλακτικα ιικα εμβολια
MXPA05006042A (es) Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores.
WO2003040168A3 (en) Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
Billeskov et al. Comparing adjuvanted H28 and modified vaccinia virus ankara expressing H28 in a mouse and a non-human primate tuberculosis model
WO2002088328A8 (en) Method for generating highly active human dendritic cells from monocytes
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
MX2022014161A (es) Vacunas contra sars-cov-2.
PL343246A1 (en) Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines
SG146662A1 (en) Method
AR030882A1 (es) Microbios que tienen una mutacion atenuante que comprenden un terminador de transcripcion
DE602006015508D1 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
Calvopina et al. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis
Kaya et al. The effects on immune response of levamisole treatment following infection of U-937 macrophages with Candida albicans